Neal D. Shore, MD, presented “Phase III HERO Trial: Once-Daily, Oral Relugolix Results in 96.7% Testosterone Suppression in Men with Advanced Prostate Cancer” for the Grand Rounds in Urology audience in November 2019.
How to cite: Shore, Neal D. “Phase III HERO Trial: Once-Daily, Oral Relugolix Results in 96.7% Testosterone Suppression in Men with Advanced Prostate Cancer” November, 2019. Accessed Apr 2026. https://grandroundsinurology.com/phase-iii-hero-trial/
Phase III HERO Trial: Once-Daily, Oral Relugolix Results in 96.7% Testosterone Suppression in Men with Advanced Prostate Cancer – Summary:
Neal D. Shore, MD, a HERO Program Steering Committee Member, discusses the results of his group’s global, prospective, randomized, phase III trial. This trial evaluated once-daily, oral relugolix, a gonadotropin-releasing hormone (GnRH) antagonist, for the treatment of advanced prostate cancer against a control arm of patients receiving 3-month leuprolide injections. The primary endpoint of sustained testosterone suppression for 48 weeks was met, as well as 6 key secondary endpoints, and the reported major adverse cardiovascular events favored relugolix over the control arm.
ABOUT THE AUTHOR
Neal D. Shore, MD, FACS, is the Medical Director at Carolina Urologic Research Center in Myrtle Beach, South Carolina. Dr. Shore also serves as a Clinical Urology Specialist at Atlantic Urology Specialists, LLC, also in Myrtle Beach, South Carolina. He is the Director of START GU Oncology Center of Excellence at the START Center for Cancer Research. He is an internationally recognized expert in systemic therapies for patients with advanced urologic cancers of the prostate, kidney, and bladder.
